Showing 4531-4540 of 5910 results for "".
- Ocuphire Completes Enrollment in MIRA-4 Pediatric Safety Trial Evaluating Nyxol for Reversal of Mydriasishttps://modernod.com/news/ocuphire-completes-enrollment-in-mira-4-pediatric-safety-trial-evaluating-nyxol-for-reversal-of-mydriasis/2480680/Ocuphire Pharma announced that it has completed enrollment in the MIRA-4 trial evaluating the safety and efficacy of Nyxol eye drops to reverse pharmacologically-induced mydriasis (RM) in 23 pediatric subjects. Ocuphire worked closely with Oculos Develop
- Alcon Launches Clareon IOL Portfolio in the UShttps://modernod.com/news/alcon-launches-clareon-iol-portfolio-in-the-us/2480677/Alcon announced the launch of the Clareon family of IOLs in the United States. Utilizing an advanced IOL material, Clareon is designed to deliver consistent visual outcomes and clarity that lasts.[1-7] The Clareon clarity is born out of a glistening-free IOL material that has among
- LumiThera Completes Acquisition of Diopsyshttps://modernod.com/news/lumithera-completes-acquisition-of-diopsys/2480675/LumiThera announced the completion of its acquisition of Diopsys, a provider of modern visual electrophysiology medical devices. Diopsys is now a wholly owned subsidiary of LumiThera. Financial terms the transaction were not disclosed. EyewireTV's covereage of the acq
- Santen Establishes its First External Research Laboratory in Europe at the UCL Institute of Ophthalmology in Londonhttps://modernod.com/news/santen-establishes-its-first-external-research-laboratory-in-europe-at-the-ucl-institute-of-ophthalmology-in-london/2480674/Santen, in partnership with UCL Institute of Ophthalmology (IoO), has announced the company’s first external research laboratory in Europe. This development comes following ongoing and committed investment from Santen
- Accure Therapeutics Licenses Neuroprotective Drug Candidate to Oculishttps://modernod.com/news/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus/2480672/Oculis and Accure Therapeutics announced a licensing agreement granting Oculis exclusive global rights to develop and commercialize ACT-01, a potentially disease-modifying therapy to protect and prevent damage to the optic
- EssilorLuxottica Closes Acquisition of Walman Opticalhttps://modernod.com/news/essilorluxottica-closes-acquisition-of-walman-optical/2480668/EssilorLuxottica announces today the closing of its acquisition of U.S.-based lab network Walman Optical, a leading lab partner to vision care practices around the country. First announced in March 2021, the acquisition will draw on EssilorLuxottica’s focus on product and service innovation
- Alpine and Shamir Extend Strategic Partnership Into Esports Worldhttps://modernod.com/news/alpine-and-shamir-extend-strategic-partnership-into-esports-world/2480654/Shamir has announced a multi-year extension to its partnership with Alpine F1 Team, becoming the optical performance partner of Alpine Esports Team. Shamir will provide ophthalmic assessments and improvement of gaming performance, and endurance through cutting edge lenses and
- Sight Sciences Launches “Don’t Wait for Too Late” Awareness Campaign for Glaucomahttps://modernod.com/news/sight-sciences-launches-dont-wait-for-too-late-awareness-campaign-for-glaucoma/2480649/Sight Sciences announced the launch of its “Don’t Wait for Too Late” educational campaign designed to raise awareness among the optometric community of minimally invasive glaucoma surgery (MIGS) as an earlier surgical intervention for glaucoma.
- Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022https://modernod.com/news/opthea-data-for-opt-302-in-patients-with-polypoidal-choroidal-vasculopathy-pcv-presented-at-angiogenesis-2022/2480640/Opthea announced data was presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference. The presentation, entitled “OPT-302 Combination Therapy with Ranibizumab for Treatment of Polypoidal Choroidal Vasculopathy,&r
- Novartis Presents Positive Results From Three Phase 3 Trials of Beovu in DMEhttps://modernod.com/news/novartis-presented-positive-results-from-three-phase-3-trials-of-beovu-in-dme/2480638/At the Angiogenesis, Exudation, and Degeneration 2022 Virtual Meeting, Novartis presented additional positive results from three phase 3 trials of Beovu in DME, including results from patients dosed at up to 16-week intervals. This was the first detailed presentation of the year 2 results&nb